Altamira Competitors

Stocks . USA . 
Stock . Altamira Therapeutics
CYTO Stock  USD 0.44  0.03  7.32%   
Altamira Therapeutics competes with Pyxis Oncology, Zura Bio, Elevation Oncology, Immix Biopharma, and Enveric Biosciences; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Altamira Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Altamira Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Altamira Therapeutics Correlation with its peers.
To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Altamira Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Altamira Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.020.445.16
Details
Intrinsic
Valuation
LowRealHigh
0.020.425.14
Details
Naive
Forecast
LowNextHigh
0.010.475.18
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.400.480.57
Details

Altamira Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Altamira Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Altamira and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Altamira Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
IMMX
+ 0.85
ELEV
ZVSA
+ 0.75
PALI
CNSP
+ 0.71
ELEV
CNSP
+ 0.68
IMMX
ZVSA
+ 0.64
ENVB
CNSP
+ 0.6
ENVB
  
High negative correlations   
PALI
- 0.27
PYXS
ZVSA
- 0.24
PYXS
IMMX
- 0.14
ZURA
CNSP
- 0.05
ZURA
CNSP
- 0.03
PYXS
ZVSA
- 0.0
EFTR

Risk-Adjusted Indicators

There is a big difference between Altamira Stock performing well and Altamira Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Altamira Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Altamira Therapeutics Competitive Analysis

The better you understand Altamira Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Altamira Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Altamira Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CYTO PYXS ZURA EFTR ELEV IMMX ENVB PALI CNSP ZVSA
 7.32 
 0.44 
Altamira
 45.03 
 2.10 
Pyxis
 1.03 
 2.93 
Zura
 30.00 
 0.13 
Effector
 5.17 
 0.61 
Elevation
 7.69 
 1.68 
Immix
 2.86 
 0.34 
Enveric
 0.41 
 2.44 
Palisade
 8.33 
 0.13 
Cns
 0.87 
 1.14 
ZyVersa
Market Volatility
(90 Days Market Risk)
Out of control
Dangerous
Very risky
Very steady
Abnormally volatile
Dangerous
Out of control
Very risky
Out of control
Abnormally volatile
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Below Average
Below Average
Dangerous
Very High
Average
Very High
Very High
Very High
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
0.77
15.19
N/A
1.79
6.48
19.53
8.33
2.59
12.34
N/A
Net Asset
7.69 M
173.73 M
100.84 M
20.54 M
89.09 M
19.93 M
4.3 M
14.05 M
1.7 M
22.11 M
EBITDA
(1.35 M)
(78.49 M)
(60.56 M)
(33.73 M)
(41.47 M)
(16.14 M)
(17.14 M)
(12.28 M)
(18.86 M)
(107.74 M)
Current Valuation
2.02 M
102.88 M
189.69 M
(4.52 M)
(37.69 M)
31.46 M
(3.59 M)
(3.95 M)
163.42 K
(433.2 K)
Price To Book
0.26
1.48
1.24
13.38
0.5
2.85
0.88
0.56
2.12
0.38
Operating Margin
N/A
-3.99
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Retained Earnings
(18.05 M)
(286.23 M)
(103.49 M)
(179.38 M)
(195.97 M)
(53.41 M)
(96.5 M)
(121.51 M)
(69.57 M)
(103.22 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
6.61 M
N/A
Beta
2.44
1.28
0.14
0.83
1.25
0.1
0.47
1.33
1.05
0.64
Number Of Employees
10
54
14
14
29
14
7
9
3
7
Shares Outstanding
3.78 M
59.47 M
63.77 M
4.7 M
59.12 M
27.51 M
9.94 M
1.33 M
40.75 M
2.34 M
Cash Flow From Operations
(11.51 M)
(70.71 M)
(15.05 M)
(29.55 M)
(56.18 M)
(11.37 M)
(14.09 M)
(11.13 M)
(14.14 M)
(8.72 M)
Total Debt
99.66 K
21.33 M
21.29 M
19.45 M
30.14 M
3.72 M
2.34 M
369 K
300.81 K
8.66 K
Return On Equity
-3.69
-0.39
-0.37
-9.47
-0.64
-1.04
-2.06
-1.1
-10.19
-1.52
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.57
-0.21
-0.21
-0.83
-0.25
-0.57
-0.8
-0.59
-2.24
-0.25
Number Of Shares Shorted
31.09 K
5.86 M
1.75 M
91.62 K
6.21 M
434.94 K
330.22 K
43.11 K
1.14 M
45.48 K
Book Value Per Share
2.37
2.59
2.34
0.21
1.17
0.82
0.71
18.3
-2.97
27.33
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
488.66 K
N/A
Total Asset
7.69 M
173.73 M
100.84 M
20.54 M
89.09 M
19.93 M
4.3 M
14.05 M
1.7 M
22.11 M
Debt To Equity
0.045
0.074
N/A
1.03
N/A
0.002
0.005
0.23
0.013
N/A
Short Ratio
0.6
10.78
5.43
0.97
9.36
2.94
0.31
0.29
0.04
0.19
Target Price
4.5
10.17
15.0
11.0
7.0
7.0
8.32
30.33
0.5
20.0
Shares Owned By Institutions
3.13
54.52
53.29
23.71
77.96
17.64
7.05
3.57
0.7
4.47
Market Capitalization
1.66 M
227.16 M
295.78 M
846.79 K
34.35 M
50.06 M
3.48 M
3.73 M
5.28 M
2.7 M
Price To Earnings To Growth
N/A
0.01
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Earning
N/A
N/A
N/A
1.03
0.16
N/A
N/A
0.16
-13.7
N/A
Price To Sales
0.64
14.07
N/A
69.65
N/A
N/A
0.0831
14.03
N/A
N/A
Net Income
(3.87 M)
(73.79 M)
(60.56 M)
(35.81 M)
(45.7 M)
(15.6 M)
(17.29 M)
(12.3 M)
(18.85 M)
(98.3 M)
Earnings Per Share
1.94
-1.06
0.57
-12.57
-0.8
-0.84
-2.42
-13.26
-352.97
491.97
Shares Owned By Insiders
0.52
24.54
31.87
2.9
0.2
40.09
6.92
1.88
1.2
0.61
Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
250 K
N/A
N/A
Working Capital
334.24 K
98.84 M
80.54 M
(5.96 M)
83.82 M
16.07 M
1.24 M
10.74 M
(4.54 M)
(6.84 M)
Cash And Equivalents
984.19 K
223.36 M
N/A
41.04 M
122.54 M
18.4 M
18.01 M
5 M
8.96 M
N/A
Cash Per Share
1.29
7.48
N/A
0.99
5.26
1.32
11.44
0.23
0.22
N/A
Gross Profit
(2.18 M)
N/A
N/A
(19.76 M)
N/A
N/A
8.15 M
N/A
N/A
N/A
Day Typical Price
0.43
2.13
2.94
0.12
0.6
1.74
0.33
2.56
0.13
1.15
Accumulation Distribution
0.0889
0.21
0.0268
0.59
0.0806
0.13
0.0882
0.19
0.0714
0.0508
Market Facilitation Index
0.04
0.49
0.08
0.1
0.05
0.24
0.03
0.54
0.01
0.06
Daily Balance Of Power
0.75
(3.51)
0.375
0.3
0.6
(0.58)
(0.33)
0.0185
1.0
(0.17)
Period Momentum Indicator
0.03
(1.72)
0.03
0.03
0.03
(0.14)
(0.01)
0.01
0.01
(0.01)
Rate Of Daily Change
1.07
0.55
1.01
1.3
1.05
0.92
0.97
1.0
1.08
0.99
Day Median Price
0.43
2.15
2.95
0.12
0.6
1.77
0.33
2.62
0.14
1.15
Price Action Indicator
0.025
(0.90)
(0.01)
0.025
0.03
(0.16)
0.01
(0.18)
N/A
(0.01)
Relative Strength Index
34.74
32.09
35.06
18.1
49.19
47.97
35.17
39.13
50.31
33.5
Coefficient Of Variation
(463.87)
(1,148)
(1,274)
N/A
(1,514)
(2,249)
(811.84)
(1,176)
(2,565)
(802.76)
Mean Deviation
3.49
3.76
3.7
N/A
3.54
3.84
3.24
3.6
4.61
4.19
Jensen Alpha
(1.01)
(0.66)
(0.45)
N/A
(0.35)
(0.30)
(0.64)
(0.36)
(0.23)
(0.83)
Total Risk Alpha
(1.64)
(1.54)
(1.02)
N/A
(0.90)
(0.98)
(1.21)
(1.08)
(1.19)
(2.13)
Standard Deviation
4.72
7.04
4.82
N/A
4.55
5.54
4.75
4.97
6.98
8.32
Kurtosis
0.816
25.35
1.76
N/A
0.155
4.07
5.72
3.07
2.12
15.14
Potential Upside
6.98
6.41
6.44
N/A
5.77
7.06
6.25
5.97
9.09
7.57
Treynor Ratio
6.04
(1.53)
(0.62)
N/A
(0.71)
(0.61)
(1.25)
0.5591
0.5883
0.4827
Maximum Drawdown
22.81
61.13
26.7
N/A
22.21
32.68
28.33
24.25
39.29
78.93
Variance
22.24
49.63
23.27
N/A
20.74
30.69
22.52
24.72
48.78
69.17
Market Risk Adjusted Performance
6.05
(1.52)
(0.61)
N/A
(0.70)
(0.60)
(1.24)
0.5691
0.5983
0.4927
Risk Adjusted Performance
(0.16)
(0.06)
(0.05)
N/A
(0.04)
(0.03)
(0.09)
(0.06)
(0.02)
(0.09)
Skewness
(0.40)
(3.79)
(0.74)
N/A
0.0819
1.3
1.63
0.4981
0.7441
0.3559
Information Ratio
(0.24)
(0.10)
(0.10)
N/A
(0.09)
(0.06)
(0.15)
(0.11)
(0.05)
(0.14)
Value At Risk
(10.87)
(7.36)
(7.94)
N/A
(8.22)
(8.22)
(7.50)
(8.55)
(11.76)
(9.60)

Altamira Therapeutics Competition Performance Charts

Five steps to successful analysis of Altamira Therapeutics Competition

Altamira Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Altamira Therapeutics in relation to its competition. Altamira Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Altamira Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Altamira Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Altamira Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Altamira Therapeutics position

In addition to having Altamira Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Adviser Favorites Thematic Idea Now

Adviser Favorites
Adviser Favorites Theme
Financial advisors frequently recommend that individuals diversify their investment portfolios with a mix of different types of stocks. These can include blue-chip stocks, growth stocks, and dividend stocks. The Adviser Favorites theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Adviser Favorites Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Altamira Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Altamira Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Altamira Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Altamira Therapeutics Stock:
How To Invest In Altamira
Details
Is Altamira Stock a good investment?
Details
What is Altamira Therapeutics' Net Worth?
Details
Largest Pharmaceutical Products Companies
View
Largest Biotechnology Companies
View
Check out Altamira Therapeutics Correlation with its peers.
To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY